Nuclear Proteasome Dilution Drives Epigenetic Clock Acceleration via Chromatin Accessibility Loss

Hypothesis

Nuclear proteasome dilution directly accelerates epigenetic aging by impairing the turnover of nuclear histone‑modifying enzymes, leading to a progressive loss of chromatin accessibility that fuels the exponential rise of DNA‑methylation‑based aging clocks.

Mechanistic Rationale

• Supervised pseudotime tools (psupertime, Sceptic) show that aging trajectories are best ordered when chronological age is used as a guide [1].
• In yeast, nuclear proteasome concentration declines faster than cytoplasmic pools and predicts individual lifespan (r=0.42) [2], suggesting that nuclear dilution is an early, upstream event.
• Mammalian epigenetic age follows exponential trajectories that match mortality risk [3]
• We propose that as the nuclear volume expands with age, proteasome concentration drops, decreasing degradation of histone acetyltransferases (HATs) and deacetylases (HDACs). The resulting imbalance alters nucleosome occupancy and reduces accessibility at CpG‑rich regions, which are substrates for DNA methyltransferases. This chromatin state shift drives the observed exponential increase in methylation age.

Testable Predictions

1. Artificially maintaining nuclear proteasome levels in aged cells will slow the exponential increase of DNA‑methylation age measured by Horvath’s clock.
2. Inducing nuclear proteasome loss in young cells will recapitulate an aged chromatin accessibility profile (reduced ATAC‑seq signal at promoters) and accelerate methylation‑clock progression.
3. The relationship between nuclear proteasome concentration and methylation age will be stronger than that between cytoplasmic proteasome levels and methylation age across donors.

Experimental Design

• Use human fibroblast or iPSC‑derived mesenchymal cultures. Engineer a doxycycline‑inducible NLS‑tagged proteasome subunit (e.g., PSMC5) to boost nuclear import upon induction.
• Generate three conditions: (a) control, (b) nuclear proteasome overexpression, (c) nuclear proteasome knockdown via CRISPRi of importin‑β1.
• At passages corresponding to early, mid, and late replicative age, collect samples for:
  • Pseudotime reconstruction using psupertime on transcriptome data (provides supervised age ordering) [1].
  • Quantitative immunoblot or fluorescence‑based measurement of nuclear vs cytoplasmic proteasome levels.
  • ATAC‑seq to assess chromatin accessibility.
  • Whole‑genome bisulfite sequencing or EPIC array to compute DNA‑methylation age.
• Perform statistical mediation analysis to test whether changes in nuclear proteasome levels mediate the effect of passage number on methylation age via accessibility scores.

Potential Outcomes and Interpretation

• If nuclear proteasome overexpression attenuates the rise of methylation age and preserves ATAC‑seq signal, the hypothesis is supported, indicating a causal link from proteostasis decline to epigenetic drift.
• If nuclear proteasome loss in young cells accelerates methylation clock and reduces accessibility, this demonstrates sufficiency.
• Lack of effect would falsify the proposed mechanistic chain, suggesting that nuclear proteasome dilution correlates with, but does not drive, epigenetic aging; alternative upstream factors (e.g., nuclear lamina changes) would then be prioritized.

This framework links a quantitative proteostasis marker to the exponential epigenetic clock, offering a concrete, falsifiable route to identify early lifespan predictors and to guide interventions that sustain nuclear proteasome activity.